|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pirastu R, Biggeri A and Comba P:
International Agency for Research on Cancer Monographs (IARC). G
Ital Med Lav Ergon. 30:83–84; author reply 86–87. 2008.(In
Italian). PubMed/NCBI
|
|
3
|
Pontisso P, Calabrese F, Benvegnù L, et
al: Overexpression of squamous cell carcinoma antigen variants in
hepatocellular carcinoma. Br J Cancer. 90:833–837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Catanzaro JM, Guerriero JL, Liu J, et al:
Elevated expression of squamous cell carcinoma antigen (SCCA) is
associated with human breast carcinoma. PLoS One. 6:e190962011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim YT, Yoon BS, Kim JW, et al:
Pretreatment levels of serum squamous cell carcinoma antigen and
urine polyamines in women with squamous cell carcinoma of the
cervix. Int J Gynaecol Obstet. 91:47–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stenman J, Hedström J, Grénman R, et al:
Relative levels of SCCA2 and SCCA1 mRNA in primary tumors predicts
recurrent disease in squamous cell cancer of the head and neck. Int
J Cancer. 95:39–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giannelli G, Fransvea E, Trerotoli P, et
al: Clinical validation of combined serological biomarkers for
improved hepatocellular carcinoma diagnosis in 961 patients. Clin
Chim Acta. 383:147–152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Whiting PF, Rutjes AW, Westwood ME,
Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt
PM: QUADAS-2 Group: QUADAS-2: A revised tool for the quality
assessment of diagnostic accuracy studies. Ann Intern Med.
155:529–536. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Devillé WL, Buntinx F, Bouter LM, et al:
Conducting systematic reviews of diagnostic studies: Didactic
guidelines. BMC Med Res Methodol. 2:92002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zamora J, Abraira V, Muriel A, Khan K and
Coomarasamy A: Meta-DiSc: a software for meta-analysis of test
accuracy data. BMC Med Res Methodol. 6:312006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Walter SD: Properties of the summary
receiver operating characteristic (SROC) curve for diagnostic test
data. Stat Med. 21:1237–1256. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pozzan C, Cardin R, Piciocchi M, et al:
Diagnostic and prognostic role of SCCA-IgM serum levels in
hepatocellular carcinoma (HCC). J Gastroenterol Hepatol.
29:1637–1644. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soyemi OM, Otegbayo JA, Ola SO, Akere A
and Soyemi T: Comparative diagnostic efficacy of serum squamous
cell carcinoma antigen in hepatocellular carcinoma. BMC Res Notes.
5:4032012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trerotoli P, Fransvea E, Angelotti U, et
al: Tissue expression of squamous cellular carcinoma antigen (SCCA)
is inversely correlated to tumor size in HCC. Mol Cancer. 8:292009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hussein MM, Ibrahim AA, Abdella HM,
Montasser IF and Hassan MI: Evaluation of serum squamous cell
carcinoma antigen as a novel biomarker for diagnosis of
hepatocellular carcinoma in Egyptian patients. Indian J Cancer.
45:167–172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giannelli G, Marinosci F, Trerotoli P, et
al: SCCA antigen combined with alpha-fetoprotein as serologic
markers of HCC. Int J Cancer. 117:506–509. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Beneduce L, Castaldi F, Marino M, et al:
Squamous cell carcinoma antigen-immunoglobulin M complexes as novel
biomarkers for hepatocellular carcinoma. Cancer. 103:2558–2565.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salman T, Raouf AA, Saleh SM, Salama M and
Mohammed AAE: Comparative study between serum alpha-fetoprotein,
VEGF and SCCA in enhancing detection of hepatocellular carcinoma in
Egyptian patients. Hepatol Int. 5:392011.
|
|
20
|
Wu X: Clinical application value of serum
squamous cell carcinoma antigen in hepatocellular carcinoma.
Wenzhou Medical University. 2007.(In Chinese).
|
|
21
|
Zhai L, Li J, Yang X, et al: Combine serum
AFP, GP73 and SCCA IgM IC to detect early hepatocellular carcinoma
of HBV related. Shandong Medical Journal. 34–37. 2014.(In
Chinese).
|
|
22
|
Chen X, Sun P and Yao X: Squamous cell
carcinoma antigen detection in the diagnosis of primary liver
cancer. Chin J Pract Med. 37:69–70. 2010.(In Chinese).
|
|
23
|
Zhai Q: Tumor markers in the diagnosis of
hepatocellular carcinoma. Chin J Prim Med Pharm. 1614–1615.
2009.(In Chinese).
|
|
24
|
Zhu J, Jiang F, Ni HB, et al: Combined
analysis of serum γ-glutamyl transferase isoenzyme II,
α-L-fucosidase and α-fetoprotein detected using a commercial kit in
the diagnosis of hepatocellular carcinoma. Exp Ther Med. 5:89–94.
2013.PubMed/NCBI
|
|
25
|
Witjes CD, van Aalten SM, Steyerberg EW,
et al: Recently introduced biomarkers for screening of
hepatocellular carcinoma: A systematic review and meta-analysis.
Hepatol Int. 7:59–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi JY, Jung SW, Kim HY, et al:
Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma
according to total-AFP. World J Gastroenterol. 19:339–346. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Y, Yin X, Ying J and Zhang B: Golgi
protein 73 versus alpha-fetoprotein as a biomarker for
hepatocellular carcinoma: A diagnostic meta-analysis. BMC Cancer.
12:172012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marrero JA and El-Serag HB:
Alpha-fetoprotein should be included in the hepatocellular
carcinoma surveillance guidelines of the American Association for
the Study of Liver Diseases. Hepatology. 53:1060–1061; author reply
1061–1062. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu JS, Wu DW, Liang S and Miao XY: GP73, a
resident Golgi glycoprotein, is sensibility and specificity for
hepatocellular carcinoma of diagnosis in a hepatitis B-endemic
Asian population. Med Oncol. 27:339–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Akutsu N, Yamamoto H, Sasaki S, et al:
Association of glypican-3 expression with growth signaling
molecules in hepatocellular carcinoma. World J Gastroenterol.
16:3521–3528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shirakawa H, Kuronuma T, Nishimura Y, et
al: Glypican-3 is a useful diagnostic marker for a component of
hepatocellular carcinoma in human liver cancer. Int J Oncol.
34:649–656. 2009.PubMed/NCBI
|
|
32
|
Zoli M, Magalotti D, Bianchi G, et al:
Efficacy of a surveillance program for early detection of
hepatocellular carcinoma. Cancer. 78:977–985. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Trevisani F, Dintino PE, Morselli-Labate
AM, et al: Serum alpha-fetoprotein for diagnosis of hepatocellular
carcinoma in patients with chronic liver disease: Influence of
HBsAg and anti-HCV status. J Hepatol. 34:570–575. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gambarin-Gelwan M, Wolf DC, Shapiro R,
Schwartz ME and Min AD: Sensitivity of commonly available screening
tests in detecting hepatocellular carcinoma in cirrhotic patients
undergoing liver transplantation. Am J Gastroenterol. 95:1535–1538.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Glas AS, Lijmer JG, Prins MH, Bonsel GJ
and Bossuyt PM: The diagnostic odds ratio: A single indicator of
test performance. J Clin Epidemiol. 56:1129–1135. 2003. View Article : Google Scholar : PubMed/NCBI
|
